BioSpace News Archive

Albany NY, United States: Peptides are mainly made up of amino acid chains which are linked with each other with the peptide bond.

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2021 on Tuesday, 12 April 2022.

Mission Therapeutics, a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes, announced it has been granted approval to take its lead USP30 DUB inhibitor, MTX652, into clinical study.

ViaDerma, Inc., announces the release of its 2021 Annual Report on the OTC Markets. The Company ended the year with $514,007 in revenue, compared to only $11,468 the previous year.

Airway Therapeutics, Inc. announced dosing of the first patient on March 28, 2022 in the Phase 1b randomized trial of AT-100 for preventative use in very preterm infants at risk for bronchopulmonary dysplasia.

Hummingbird Diagnostics GmbH announced the publication of a study in the journal npj Precision Oncology that describes the discovery and validation of miRisk, a first-of-its-kind microRNA biomarker signature that offers the prospect of a blood-based companion diagnostic for immunotherapy in advanced non-small cell lung cancer.

IAMA Therapeutics announced the formation of a Scientific Advisory Board consisting of world-renowned experts in computational chemistry, protein drug design, and neurodevelopmental disorders.

Jaguar Health, Inc. announced that the company has entered an agreement with Quadri Pharmaceuticals Store LLC that grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for specified human indications of crofelemer in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates.

ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, published its Annual Report 2021 to Shareholders.

Trevena, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2021, and provided an overview of its 2021 and 2022 year-to-date operational highlights.